Retinoids, the natural and synthetic analogs of vitamin A, can block the phenotypic expression of cancer in vitro and can inhibit growth and induce differentiation in many animal model systems, including urinary bladder tumors. Noninvasive bladder tumors are prone to recurrence (40-80%), which can occur anywhere in the urothelial lining (polychronotropism, field effect). Previous pilot studies in superficial bladder tumors have suggested that natural or first-generation synthetic retinoids might be useful in preventing the risk of recurrence, but toxicity was severe and dose limiting. Fenretinide (4-hydroxyphenylretinamide) (4-HPR), a more recently developed synthetic retinoid, has shown to be a potent anticarcinogenetic agent in preclinical bladder cancer models. Moreover, preliminary results of a large breast cancer chemopreventive trial currently in progress in Italy have shown that the drug is well tolerated. In the proposed pilot study, patients with resected superficial tumors of the urothelial tract and negative cystoscopy will be randomized to 4-HPR (200 mg day for 2 years) or control in order to evaluate the flow cytometric variations through repeated bladder washings. This is a non invasive diagnostic procedure which can be frequently repeated and allows reliable studies of flow cytometry (FCM) for a rapid and objective quantitation of the DNA content and proliferative activity of the tumor cell population. About 50% of patients with previous history of superficial tumors have abnormal DNA content (either DNA aneuploid clones or elevated S phase fraction) in absence of visible lesions. In light of the retinoid activity on cell differentiation and proliferation, it seems appropriate to study the ability of the synthetic retinoid 4-HPR to modulate DNA ploidy and proliferation. the study is conceived as a pilot study with intermediate end-points, which, in case of demonstrated effects by the chemopreventive agent, should be followed by a phase III double- blind clinical trial aimed at evaluating the ability of 4-HPR to reduce the risk of superficial recurrence and progression to invasive cancer in a population at risk.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01CA056457-01
Application #
3549832
Study Section
Special Emphasis Panel (SRC (50))
Project Start
1992-08-01
Project End
1995-07-31
Budget Start
1992-08-01
Budget End
1993-07-31
Support Year
1
Fiscal Year
1992
Total Cost
Indirect Cost
Name
National Cancer Institute
Department
Type
DUNS #
City
Genoa
State
Country
Italy
Zip Code
Puntoni, Matteo; Zanardi, Silvia; Branchi, Daniela et al. (2007) Prognostic effect of DNA aneuploidy from bladder washings in superficial bladder cancer. Cancer Epidemiol Biomarkers Prev 16:979-83
Serrano, Davide; Baglietto, Laura; Johansson, Harriet et al. (2005) Effect of the synthetic retinoid fenretinide on circulating free prostate-specific antigen, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer. Clin Cancer Res 11:2083-8
Baglietto, L; Torrisi, R; Arena, G et al. (2000) Ocular effects of fenretinide, a vitamin A analog, in a chemoprevention trial of bladder cancer. Cancer Detect Prev 24:369-75
Decensi, A; Torrisi, R; Bruno, S et al. (2000) Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point. Cancer Epidemiol Biomarkers Prev 9:1071-8
Torrisi, R; Mezzetti, M; Johansson, H et al. (2000) Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-i, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial. Int J Cancer 87:601-5
Decensi, A; Torrisi, R; Gozza, A et al. (1999) Effect of fenretinide on bone mineral density and metabolism in women with early breast cancer. Breast Cancer Res Treat 53:145-51
Bruno, S; Torrisi, R; Costantini, M et al. (1999) Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial. J Cell Biochem 76:311-21
Decensi, A; Torrisi, R; Fontana, V et al. (1998) Correlation between plasma transforming growth factor-beta 1 and second primary breast cancer in a chemoprevention trial. Eur J Cancer 34:999-1003
Torrisi, R; Parodi, S; Fontana, V et al. (1994) Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients. Cancer Epidemiol Biomarkers Prev 3:507-10
Torrisi, R; Pensa, F; Orengo, M A et al. (1993) The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients. Cancer Res 53:4769-71